Study of NovaDerm in burn patients
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Human skin replacement-Regenicin (Primary)
- Indications Burns
- Focus Adverse reactions
- Sponsors Regenicin
- 18 Jan 2017 According to a Regenicin media release, companay is planning to Schedule 10 subjects at two burn centers. Grafting will be performed on subjects in this trial in 2017.
- 01 Nov 2016 According to a Regenicin Inc. media release, the company has completed pre-IND meeting with the FDA Office of Cellular, Tissue, and Gene Therapies (OCTGT) in the Center for Biologics Evaluation and Research (CBER) on October 27th, 2016 regarding NovaDerm.
- 12 Oct 2016 According to a Regenicin Inc., media release the company has scheduled a Pre-IND meeting with FDA Office on 27th Oct 2016 regarding the development of NovaDerm.